Drug Overview
Evinacumab (Regeneron) is a monoclonal antibody (MAb) that inhibits angiopoietin-like 3 inhibitor (ANGPTL3). ANGPTL3 is secreted naturally by the liver and acts as a partial inhibitor of lipoprotein lipase and endothelial lipase. These enzymes are involved in the degradation of lipoproteins including low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) particles.
By inhibiting ANGPTL3, evinacumab reduces the inhibition of lipoprotein lipase and endothelial lipase enzymes, and allows for the enzymes to continue to degrade lipoproteins. The uninhibited degradation of the lipoproteins by the enzymes results in a reduction in lipoproteins.
Evinacumab (Regeneron) is a monoclonal antibody (MAb) that inhibits angiopoietin-like 3 inhibitor (ANGPTL3). ANGPTL3 is secreted naturally by the liver and acts as a partial inhibitor of lipoprotein lipase and endothelial lipase. These enzymes are involved in the degradation of lipoproteins including low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) particles.
By inhibiting ANGPTL3, evinacumab reduces the inhibition of lipoprotein lipase and endothelial lipase enzymes, and allows for the enzymes to continue to degrade lipoproteins. The uninhibited degradation of the lipoproteins by the enzymes results in a reduction in lipoproteins.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
